Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 16 | 2024 | 1324 | 2.990 |
Why?
|
| HIV Infections | 22 | 2024 | 5097 | 2.250 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 8 | 2024 | 85 | 1.920 |
Why?
|
| Pyridones | 9 | 2024 | 100 | 1.840 |
Why?
|
| Piperazines | 8 | 2024 | 82 | 1.820 |
Why?
|
| Oxazines | 8 | 2024 | 81 | 1.820 |
Why?
|
| Obesity | 6 | 2024 | 367 | 1.770 |
Why?
|
| Epidemics | 2 | 2024 | 65 | 1.590 |
Why?
|
| Anti-Obesity Agents | 1 | 2024 | 1 | 0.940 |
Why?
|
| Tenofovir | 10 | 2024 | 171 | 0.900 |
Why?
|
| HIV-1 | 6 | 2024 | 1260 | 0.850 |
Why?
|
| Humans | 26 | 2024 | 14537 | 0.820 |
Why?
|
| Research Personnel | 2 | 2021 | 19 | 0.810 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 117 | 0.740 |
Why?
|
| Folic Acid | 1 | 2021 | 12 | 0.740 |
Why?
|
| Drug Interactions | 1 | 2021 | 31 | 0.730 |
Why?
|
| Weight Gain | 5 | 2024 | 77 | 0.710 |
Why?
|
| Personnel Selection | 1 | 2018 | 1 | 0.640 |
Why?
|
| Interdisciplinary Research | 1 | 2018 | 2 | 0.630 |
Why?
|
| Social Networking | 1 | 2018 | 8 | 0.630 |
Why?
|
| Mentors | 1 | 2018 | 16 | 0.620 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2021 | 196 | 0.620 |
Why?
|
| Ambulatory Care | 1 | 2018 | 54 | 0.600 |
Why?
|
| Lost to Follow-Up | 1 | 2018 | 62 | 0.600 |
Why?
|
| Patient Compliance | 1 | 2018 | 120 | 0.580 |
Why?
|
| Emtricitabine | 5 | 2024 | 78 | 0.520 |
Why?
|
| Benzoxazines | 4 | 2024 | 123 | 0.500 |
Why?
|
| Anti-Retroviral Agents | 5 | 2024 | 551 | 0.500 |
Why?
|
| Alkynes | 3 | 2024 | 117 | 0.470 |
Why?
|
| Cyclopropanes | 3 | 2024 | 123 | 0.460 |
Why?
|
| Female | 12 | 2024 | 9103 | 0.450 |
Why?
|
| Outpatients | 2 | 2023 | 38 | 0.430 |
Why?
|
| Treatment Outcome | 4 | 2023 | 889 | 0.420 |
Why?
|
| South Africa | 9 | 2024 | 7596 | 0.420 |
Why?
|
| Adult | 11 | 2024 | 5913 | 0.390 |
Why?
|
| Adenine | 5 | 2023 | 91 | 0.350 |
Why?
|
| Pregnancy | 4 | 2021 | 1862 | 0.310 |
Why?
|
| Alanine | 3 | 2023 | 31 | 0.290 |
Why?
|
| Research Design | 2 | 2023 | 124 | 0.250 |
Why?
|
| Triazoles | 1 | 2024 | 20 | 0.240 |
Why?
|
| Weight Loss | 1 | 2024 | 12 | 0.230 |
Why?
|
| Creatinine | 1 | 2024 | 53 | 0.220 |
Why?
|
| Thiazoles | 1 | 2022 | 6 | 0.210 |
Why?
|
| Male | 7 | 2024 | 6754 | 0.200 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2024 | 472 | 0.190 |
Why?
|
| Education, Graduate | 1 | 2021 | 10 | 0.190 |
Why?
|
| Social Stigma | 1 | 2021 | 80 | 0.190 |
Why?
|
| Africa | 2 | 2021 | 376 | 0.190 |
Why?
|
| Stillbirth | 1 | 2021 | 83 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 265 | 0.180 |
Why?
|
| Phosphorous Acids | 1 | 2019 | 14 | 0.170 |
Why?
|
| Lamivudine | 3 | 2024 | 89 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 529 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 296 | 0.160 |
Why?
|
| Societies, Scientific | 1 | 2018 | 1 | 0.160 |
Why?
|
| Clinical Medicine | 1 | 2018 | 1 | 0.160 |
Why?
|
| HIV Integrase Inhibitors | 3 | 2024 | 33 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2018 | 49 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2018 | 149 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.150 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 472 | 0.150 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 370 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2018 | 240 | 0.130 |
Why?
|
| Retrospective Studies | 1 | 2018 | 799 | 0.120 |
Why?
|
| Drug Substitution | 2 | 2024 | 33 | 0.120 |
Why?
|
| Middle Aged | 4 | 2024 | 3601 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2018 | 1748 | 0.110 |
Why?
|
| Pharmacogenetics | 2 | 2023 | 31 | 0.100 |
Why?
|
| Infant | 1 | 2018 | 2244 | 0.100 |
Why?
|
| Prodrugs | 2 | 2021 | 10 | 0.090 |
Why?
|
| Young Adult | 3 | 2024 | 2498 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 279 | 0.080 |
Why?
|
| Viral Load | 2 | 2020 | 819 | 0.060 |
Why?
|
| Glucuronosyltransferase | 1 | 2024 | 6 | 0.060 |
Why?
|
| Uganda | 1 | 2024 | 197 | 0.050 |
Why?
|
| Interleukins | 1 | 2023 | 3 | 0.050 |
Why?
|
| Rilpivirine | 1 | 2023 | 7 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 198 | 0.050 |
Why?
|
| Overweight | 1 | 2023 | 87 | 0.050 |
Why?
|
| Adolescent | 2 | 2020 | 2985 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2022 | 35 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2023 | 321 | 0.050 |
Why?
|
| Models, Educational | 1 | 2021 | 3 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 12 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 112 | 0.050 |
Why?
|
| Comorbidity | 1 | 2021 | 188 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2021 | 99 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2024 | 1160 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 106 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 124 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2022 | 278 | 0.040 |
Why?
|
| Focus Groups | 1 | 2021 | 196 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 111 | 0.040 |
Why?
|
| Developing Countries | 1 | 2023 | 400 | 0.040 |
Why?
|
| Uracil | 1 | 2019 | 7 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 153 | 0.040 |
Why?
|
| Risk Factors | 1 | 2023 | 1475 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 107 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 1422 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 967 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 303 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1192 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 656 | 0.030 |
Why?
|